Cortancyl
( DrugBank: Cortancyl / KEGG DRUG: Prednisone acetate )
3 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
162 | 類天疱瘡(後天性表皮水疱症を含む。) | 2 |
35. 天疱瘡
臨床試験数 : 99 / 薬物数 : 124 - (DrugBank : 36) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 169
Showing 1 to 2 of 2 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2018-001417-32-FR (EUCTR) | 13/07/201820180713 | 11/06/201820180611 | Long-term Follow-up of patients participants with pemphigus From Study RITUXIMAB3 | Long-term Follow-up of patients participants with pemphigus From Study RITUXIMAB3. Immunological, clinical and medicoeconomic evaluation Long-term Follow-up of patients participants with pemphigus From Study RITUXIMAB3. Immunological, cl ... | Patients with Bullous pemphigoid included in RITUXIMAB3 study MedDRA version: 20.0;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Patients with Bullous pemphigoid included in RITUXIMAB3 study MedDRA version: 20.0;Level: LLT;Classi ... | Trade Name: MABTHERA INN or Proposed INN: RITUXIMAB Trade Name: Prednisone Product Name: CORTANCYL 20 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Prednisone Product Name: CORTANCYL 20 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: MABTHERA INN or Proposed INN: RITUXIMAB Trade Name: Prednisone Product Name: CORTANCYL20 mg ... | CHU-Hôpitaux de Rouen | NULL | Not Recruiting | Female: yes Male: yes | 77 | Phase 3 | France | ||
2 | EUCTR2008-005266-31-FR (EUCTR) | 06/02/200920090206 | 13/03/200920090313 | COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A UNE CORTICOTHERAPIE GENERALE COURTE PAR RAPPORT A UNE CORTICOTHERAPIE GENERALE DE LONGUE DUREE CHEZ LES PATIENTS ATTEINTS DE PEMPHIGUS - Rituximab III COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A ... | COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A UNE CORTICOTHERAPIE GENERALE COURTE PAR RAPPORT A UNE CORTICOTHERAPIE GENERALE DE LONGUE DUREE CHEZ LES PATIENTS ATTEINTS DE PEMPHIGUS - Rituximab III COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A ... | Pemphogoide bulleuse MedDRA version: 9.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid Pemphogoide bulleuse MedDRA version: 9.1;Level: LLT;Classification code 10006567;Term: Bullous pemph ... | Trade Name: mabthéra Product Name: mathéra Trade Name: Prednisone Product Name: CORTANCYL 20 mg | CHU-Hôpitaux de Rouen | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | France |
41. 巨細胞性動脈炎
臨床試験数 : 131 / 薬物数 : 139 - (DrugBank : 36) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 125
Showing 1 to 10 of 17 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2017-002988-18-FI (EUCTR) | 02/10/201920191002 | 12/09/201920190912 | Evaluation of Efficacy and Safety of Sarilumab in Patients with GCA | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sariluma ... | Giant Cell Arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Giant Cell Arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell a ... | Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Cortancyl ® 5 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 1 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 20 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 5 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Kevzara ® INN or Proposed INN: SARILUM ... | Sanofi-Aventis Recherche & Développement | NULL | Not Recruiting | Female: yes Male: yes | 508 | Phase 3 | Portugal;Serbia;United States;Estonia;Spain;Israel;Russian Federation;Italy;Switzerland;France;Denmark;Australia;Netherlands;Slovenia;Finland;Austria;United Kingdom;Hungary;Canada;Argentina;Belgium;Croatia;Germany;Norway;Sweden Portugal;Serbia;United States;Estonia;Spain;Israel;Russian Federation;Italy;Switzerland;France;Denma ... | ||
2 | EUCTR2017-002988-18-HR (EUCTR) | 15/04/201920190415 | 17/05/201920190517 | Evaluation of Efficacy and Safety of Sarilumab in Patients with GCA | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sariluma ... | Giant Cell Arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Giant Cell Arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell a ... | Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Cortancyl ® 5 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 1 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 20 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 5 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Kevzara ® INN or Proposed INN: SARILUM ... | Sanofi-Aventis Recherche & Développement | NULL | Not Recruiting | Female: yes Male: yes | 508 | Phase 3 | United States;Portugal;Estonia;Slovenia;Finland;Spain;Austria;Russian Federation;Chile;Israel;United Kingdom;Switzerland;Italy;France;Hungary;Canada;Argentina;Belgium;Croatia;Australia;Denmark;Netherlands;Germany;Sweden United States;Portugal;Estonia;Slovenia;Finland;Spain;Austria;Russian Federation;Chile;Israel;United ... | ||
3 | EUCTR2017-002988-18-SI (EUCTR) | 22/03/201920190322 | 19/12/201820181219 | Evaluation of Efficacy and Safety of Sarilumab in Patients with GCA | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sariluma ... | Giant Cell Arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Giant Cell Arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell a ... | Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Cortancyl ® 5 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 1 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 20 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 5 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Kevzara ® INN or Proposed INN: SARILUM ... | Sanofi-Aventis Recherche & Développement | NULL | Not Recruiting | Female: yes Male: yes | 508 | Phase 3 | United States;Portugal;Estonia;Slovenia;Finland;Spain;Austria;Russian Federation;Israel;Chile;United Kingdom;Switzerland;Italy;France;Hungary;Canada;Argentina;Belgium;Croatia;Australia;Denmark;Netherlands;Germany;Sweden United States;Portugal;Estonia;Slovenia;Finland;Spain;Austria;Russian Federation;Israel;Chile;United ... | ||
4 | EUCTR2017-002988-18-GB (EUCTR) | 04/03/201920190304 | 20/06/201920190620 | Evaluation of Efficacy and Safety of Sarilumab in Patients with GCA | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sariluma ... | Giant Cell Arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 100000004866 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Giant Cell Arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell a ... | Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Cortancyl ® 5 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 1 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 20 mg Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Kevzara ® INN or Proposed INN: SARILUM ... | Sanofi-Aventis Recherche & Développement | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 508 | Phase 3 | Portugal;United States;Estonia;Slovenia;Spain;Austria;Russian Federation;Israel;Chile;Italy;United Kingdom;Switzerland;France;Hungary;Canada;Argentina;Belgium;Croatia;Denmark;Australia;Netherlands;Germany;Sweden Portugal;United States;Estonia;Slovenia;Spain;Austria;Russian Federation;Israel;Chile;Italy;United K ... | ||
5 | EUCTR2017-002988-18-PT (EUCTR) | 25/02/201920190225 | 05/11/201820181105 | Evaluation of Efficacy and Safety of Sarilumab in Patients with GCA | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sariluma ... | Giant Cell Arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Giant Cell Arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell a ... | Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Cortancyl ® 5 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 1 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 20 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 5 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Kevzara ® INN or Proposed INN: SARILUM ... | Sanofi-Aventis Recherche & Développement | NULL | Not Recruiting | Female: yes Male: yes | 508 | Phase 3 | United States;Portugal;Estonia;Slovenia;Finland;Spain;Austria;Russian Federation;Israel;Chile;United Kingdom;Switzerland;Italy;France;Hungary;Canada;Argentina;Belgium;Croatia;Australia;Denmark;Netherlands;Germany;Sweden United States;Portugal;Estonia;Slovenia;Finland;Spain;Austria;Russian Federation;Israel;Chile;United ... | ||
6 | EUCTR2017-002988-18-AT (EUCTR) | 19/02/201920190219 | 28/09/201820180928 | Evaluation of Efficacy and Safety of Sarilumab in Patients with GCA | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sariluma ... | Giant Cell Arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Giant Cell Arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell a ... | Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Cortancyl ® 5 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 1 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 20 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 5 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Kevzara ® INN or Proposed INN: SARILUM ... | Sanofi-Aventis Recherche & Développement | NULL | Not Recruiting | Female: yes Male: yes | 508 | Phase 3 | United States;Portugal;Estonia;Slovenia;Finland;Spain;Austria;Russian Federation;Chile;Israel;United Kingdom;Switzerland;Italy;France;Hungary;Canada;Argentina;Belgium;Croatia;Australia;Denmark;Netherlands;Germany;Sweden United States;Portugal;Estonia;Slovenia;Finland;Spain;Austria;Russian Federation;Chile;Israel;United ... | ||
7 | EUCTR2017-002988-18-FR (EUCTR) | 14/01/201920190114 | 09/10/201820181009 | Evaluation of Efficacy and Safety of Sarilumab in Patients with GCA | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sariluma ... | Giant Cell Arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Giant Cell Arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell a ... | Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Cortancyl ® 5 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 1 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 20 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 5 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Kevzara ® INN or Proposed INN: SARILUM ... | Sanofi-Aventis Recherche & Développement | NULL | Not Recruiting | Female: yes Male: yes | 508 | Phase 3 | United States;Portugal;Estonia;Slovenia;Finland;Spain;Austria;Russian Federation;Chile;Israel;United Kingdom;Switzerland;Italy;France;Hungary;Canada;Argentina;Belgium;Croatia;Australia;Denmark;Netherlands;Germany;Sweden United States;Portugal;Estonia;Slovenia;Finland;Spain;Austria;Russian Federation;Chile;Israel;United ... | ||
8 | EUCTR2017-002988-18-DK (EUCTR) | 04/01/201920190104 | 29/09/201820180929 | Evaluation of Efficacy and Safety of Sarilumab in Patients with GCA | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sariluma ... | Giant Cell Arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Giant Cell Arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell a ... | Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Cortancyl ® 5 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 1 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 20 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 5 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Kevzara ® INN or Proposed INN: SARILUM ... | Sanofi-Aventis Recherche & Développement | NULL | Not Recruiting | Female: yes Male: yes | 508 | Phase 3 | United States;Portugal;Estonia;Slovenia;Finland;Spain;Austria;Russian Federation;Chile;Israel;United Kingdom;Switzerland;Italy;France;Hungary;Canada;Argentina;Belgium;Croatia;Denmark;Australia;Netherlands;Germany;Sweden United States;Portugal;Estonia;Slovenia;Finland;Spain;Austria;Russian Federation;Chile;Israel;United ... | ||
9 | EUCTR2018-000344-25-FR (EUCTR) | 18/12/201820181218 | 10/08/201820180810 | Essai, randomisé, contrôlé, ouvert, de deux schémas standardisés de décroissance, respectivement rapide (nord-américain) et lent (européen), de cortisone dans l’artérite à cellules géantes. Essai, randomisé, contrôlé, ouvert, de deux schémas standardisés de décroissance, respectivement rap ... | Essai, randomisé, contrôlé, ouvert, de deux schémas standardisés de décroissance, respectivement rapide (nord-américain) et lent (européen), de cortisone dans l’artérite à cellules géantes. - CORTODOSE Essai, randomisé, contrôlé, ouvert, de deux schémas standardisés de décroissance, respectivement rap ... | Patients atteints d’artérite à cellules géantes MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 100000004866 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Patients atteints d’artérite à cellules géantes MedDRA version: 20.0;Level: LLT;Classification code ... | Trade Name: CORTANCYL Product Name: CORTANCYL | CHU CAEN | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 150 | Phase 3 | France | ||
10 | EUCTR2017-002988-18-NL (EUCTR) | 10/12/201820181210 | 01/11/201820181101 | Evaluation of Efficacy and Safety of Sarilumab in Patients with GCA | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sariluma ... | Giant Cell Arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Giant Cell Arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell a ... | Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Cortancyl ® 5 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 1 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 20 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Cortancyl ® 5 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Kevzara ® INN or Proposed INN: SARILUMAB Trade Name: Kevzara ® INN or Proposed INN: SARILUM ... | Sanofi-Aventis Recherche & Développement | NULL | Not Recruiting | Female: yes Male: yes | 508 | Phase 3 | United States;Portugal;Estonia;Slovenia;Finland;Spain;Austria;Russian Federation;Israel;Chile;United Kingdom;Switzerland;Italy;France;Hungary;Canada;Argentina;Belgium;Croatia;Australia;Denmark;Netherlands;Germany;Sweden United States;Portugal;Estonia;Slovenia;Finland;Spain;Austria;Russian Federation;Israel;Chile;United ... |
162. 類天疱瘡(後天性表皮水疱症を含む。)
臨床試験数 : 90 / 薬物数 : 122 - (DrugBank : 47) / 標的遺伝子数 : 34 - 標的パスウェイ数 : 144
Showing 1 to 2 of 2 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2018-001417-32-FR (EUCTR) | 13/07/201820180713 | 11/06/201820180611 | Long-term Follow-up of patients participants with pemphigus From Study RITUXIMAB3 | Long-term Follow-up of patients participants with pemphigus From Study RITUXIMAB3. Immunological, clinical and medicoeconomic evaluation Long-term Follow-up of patients participants with pemphigus From Study RITUXIMAB3. Immunological, cl ... | Patients with Bullous pemphigoid included in RITUXIMAB3 study MedDRA version: 20.0;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Patients with Bullous pemphigoid included in RITUXIMAB3 study MedDRA version: 20.0;Level: LLT;Classi ... | Trade Name: MABTHERA INN or Proposed INN: RITUXIMAB Trade Name: Prednisone Product Name: CORTANCYL 20 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Prednisone Product Name: CORTANCYL 20 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: MABTHERA INN or Proposed INN: RITUXIMAB Trade Name: Prednisone Product Name: CORTANCYL20 mg ... | CHU-Hôpitaux de Rouen | NULL | Not Recruiting | Female: yes Male: yes | 77 | Phase 3 | France | ||
2 | EUCTR2008-005266-31-FR (EUCTR) | 06/02/200920090206 | 13/03/200920090313 | COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A UNE CORTICOTHERAPIE GENERALE COURTE PAR RAPPORT A UNE CORTICOTHERAPIE GENERALE DE LONGUE DUREE CHEZ LES PATIENTS ATTEINTS DE PEMPHIGUS - Rituximab III COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A ... | COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A UNE CORTICOTHERAPIE GENERALE COURTE PAR RAPPORT A UNE CORTICOTHERAPIE GENERALE DE LONGUE DUREE CHEZ LES PATIENTS ATTEINTS DE PEMPHIGUS - Rituximab III COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A ... | Pemphogoide bulleuse MedDRA version: 9.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid Pemphogoide bulleuse MedDRA version: 9.1;Level: LLT;Classification code 10006567;Term: Bullous pemph ... | Trade Name: mabthéra Product Name: mathéra Trade Name: Prednisone Product Name: CORTANCYL 20 mg | CHU-Hôpitaux de Rouen | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | France |